CYTOKINETICS INC
Cytokinetics is a biopharmaceutical company that discovers, develops and commercializes small-molecule medicines targeting muscle function for people with cardiovascular and neuromuscular diseases. Its first commercial product, MYQORZO (aficamten), is an oral cardiac myosin inhibitor approved to treat adults with symptomatic obstructive hypertrophic cardiomyopathy. The company also develops aficamten for other conditions and has research programs involving omecamtiv mecarbil, a cardiac myosin activator, ulacamten, a cardiac myosin inhibitor, and CK-089, a skeletal muscle troponin activator. Cytokinetics sells MYQORZO in the United States and is preparing to commercialize it in Europe. It has licensing and collaboration arrangements for aficamten in China and Taiwan with Sanofi and in Japan with Bayer. These arrangements, along with sales of its medicines, are ways it makes money. Cytokinetics is headquartered in South San Francisco, California.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Cytokinetics reported 3Q 2026 revenue of $47.6M, up from $1.9M a year earlier, driven by $44.5M in MYQORZO product revenue. Net loss narrowed to $190.1M from $306.2M. MYQORZO launched in Germany and China, with EU, UK, and Canada approvals. ACACIA-HCM study met endpoints, and FDA decisions on expanded MYQORZO label and CK-089 trials are pending.
CYTOKINETICS INC (CYTK) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Cytokinetics Reports Third Quarter 2026 Financial Results and Provides Business Update MYQORZO ® (aficamten) Net Product Revenue of $44.5 Million Expect to Submit Supplemental NDA for Aficamten in Non-Obstructive HCM in Q4 2026 and Type II Variation in the European U
AstraZeneca (AZN) received FDA approval for Ultomiris in IgA nephropathy, with a 43.4% reduction in proteinuria. Merck (MRK) got EU approval for KEYTRUDA plus Padcev in bladder cancer, showing a 35% reduction in death risk. Alvotech (ALVO) approved a new manufacturing process for SIMLANDI. Cytokinetics (CYTK) won Health Canada approval for MYQORZO in obstructive HCM. Viatris (VTRS) approved RYZUMVI for presbyopia. Enlivex (ENLV) and EyePoint (EYPT) announced significant workforce reductions.
Over the past 7 days, AlphAI's AI scored 6 news stories mentioning CYTK (CYTOKINETICS INC). Coverage has skewed bullish: 3 bullish, 2 neutral, and 1 bearish.
Recent CYTK coverage spans financial news, earnings and regulation.
In the last 30 days, CYTK insiders filed 5 SEC Form 4 transactions — no purchases and 5 sales ($1.6M). The most active reporter was Malik Fady Ibraham, EVP Research & Development, with 3 filings. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
Revenue surge and loss improvement may lift the stock.
Earnings beat and strong cash position suggest upside potential.
Canadian clearance adds another market for the drug.
The announcement sets the timeline for the upcoming earnings release, likely prompting modest positioning by traders ahead of the report.
HC Wainwright & Co. maintained a Buy rating on Cytokinetics (CYTK) with a $140 price target, suggesting a 126% upside from the Oct 16 close. The firm cited strong clinical data from the Phase 3 ACACIA-HCM trial and promising market potential for aficamten, highlighting its benefits for hypertrophic cardiomyopathy patients.
AlphAI scores every news story that mentions CYTK with an AI model for sentiment and relevance, and aggregates insider trades from CYTOKINETICS INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
Cytokinetics reported 3Q 2026 revenue of $47.6M, up from $1.9M a year earlier, driven by $44.5M in MYQORZO product revenue. Net loss narrowed to $190.1M from $306.2M. MYQORZO launched in Germany and China, with EU, UK, and Canada approvals. ACACIA-HCM study met endpoints, and FDA decisions on expanded MYQORZO label and CK-089 trials are pending.
CYTOKINETICS INC (CYTK) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Cytokinetics Reports Third Quarter 2026 Financial Results and Provides Business Update MYQORZO ® (aficamten) Net Product Revenue of $44.5 Million Expect to Submit Supplemental NDA for Aficamten in Non-Obstructive HCM in Q4 2026 and Type II Variation in the European U
AstraZeneca (AZN) received FDA approval for Ultomiris in IgA nephropathy, with a 43.4% reduction in proteinuria. Merck (MRK) got EU approval for KEYTRUDA plus Padcev in bladder cancer, showing a 35% reduction in death risk. Alvotech (ALVO) approved a new manufacturing process for SIMLANDI. Cytokinetics (CYTK) won Health Canada approval for MYQORZO in obstructive HCM. Viatris (VTRS) approved RYZUMVI for presbyopia. Enlivex (ENLV) and EyePoint (EYPT) announced significant workforce reductions.
Cytokinetics (CYTK) will release Q3 2026 results on Nov. 4, followed by a management call at 4:30 PM ET. The company develops cardiovascular treatments, including the approved MYQORZO for hypertrophic cardiomyopathy and investigational drugs omecamtiv mecarbil and ulacamten. A Phase 3 trial for aficamten in non-obstructive HCM showed positive results, with a supplemental drug application planned for Q4 2026.
HC Wainwright & Co. maintained a Buy rating on Cytokinetics (CYTK) with a $140 price target, suggesting a 126% upside from the Oct 16 close. The firm cited strong clinical data from the Phase 3 ACACIA-HCM trial and promising market potential for aficamten, highlighting its benefits for hypertrophic cardiomyopathy patients.
Cytokinetics (CYTK) announced Health Canada approved MYQORZO (aficamten) for treating symptomatic obstructive hypertrophic cardiomyopathy (oHCM) in adults. This is the fifth approval for MYQORZO in less than a year, following U.S., China, EU, and UK approvals. The approval is based on positive Phase 3 trial results showing improved exercise capacity and symptoms. MYQORZO is a once-daily oral cardiac myosin inhibitor.
Insiders at Cytokinetics (CYTK), International Seaways (INSW), BJ’s (BJ), Grace (GRCE), and PBF (PBF) reported significant stock trades. Cytokinetics director sold 7,500 shares for $471,600. International Seaways shareholder sold 1.1M shares for $107.3M. BJ’s CEO sold 192,584 shares for $19.7M. Grace shareholder bought 85,697 shares for $165.6K. PBF Energy rep sold 170,000 shares for $14.96M.
William Blair initiated coverage on Cytokinetics (NASDAQ:CYTK) with an Outperform rating and $101 price target, citing 58% upside potential. The firm expects commercial launch of MYQORZO by 2027 and $3.74B sales by 2032. Other analysts maintain bullish views, while the company faces legal action against Bristol-Myers Squibb and MyoKardia.
UBS reduced its price target for Cytokinetics (CYTK) to $104 from $115 but kept a Buy rating. The stock trades at $61.62, below the revised target and analyst consensus. UBS sees potential in Cytokinetics' drugs for hypertrophic cardiomyopathy. The company's shares have underperformed recently, down 7% in six months. Cytokinetics reported Q2 Myqorzo sales of $25.3M, exceeding estimates. Barclays raised its target to $110, while other analysts maintained Buy ratings with higher targets.
Cytokinetics (CYTK) reported new data from ACACIA-HCM trial showing aficamten improved exercise performance and safety. The company plans to submit a supplemental NDA to the FDA this quarter. According to the company, the data supports efficacy and safety.
